Department of Biochemistry, University of Missouri-Columbia, Columbia, MO, USA.
Departments of Biochemistry and Child Health, University of Missouri-Columbia, 117 Schweitzer Hall, Columbia, MO, 65211, USA.
Calcif Tissue Int. 2024 Dec;115(6):847-862. doi: 10.1007/s00223-024-01213-4. Epub 2024 Apr 19.
Osteogenesis imperfecta (OI) is a rare heritable connective tissue disorder of skeletal fragility with an incidence of roughly 1:15,000. Approximately 85% of the pathogenic variants responsible for OI are in the type I collagen genes, COL1A1 and COL1A2, with the remaining pathogenic OI variants spanning at least 20 additional genetic loci that often involve type I collagen post-translational modification, folding, and intracellular transport as well as matrix incorporation and mineralization. In addition to being the most abundant collagen in the body, type I collagen is an important structural and extracellular matrix signaling molecule in multiple organ systems and tissues. Thus, OI disease-causing variants result not only in skeletal fragility, decreased bone mineral density (BMD), kyphoscoliosis, and short stature, but can also result in hearing loss, dentinogenesis imperfecta, blue gray sclera, cardiopulmonary abnormalities, and muscle weakness. The extensive genetic and clinical heterogeneity in OI has necessitated the generation of multiple mouse models, the growing awareness of non-skeletal organ and tissue involvement, and OI being more broadly recognized as a type I collagenopathy.This has driven the investigation of mutation-specific skeletal and extra-skeletal manifestations and broadened the search of potential mechanistic therapeutic strategies. The purpose of this review is to outline several of the extra-skeletal manifestations that have recently been characterized through the use of genetically and phenotypically heterogeneous mouse models of osteogenesis imperfecta, demonstrating the significant potential impact of OI disease-causing variants as a collagenopathy (affecting multiple organ systems and tissues), and its implications to overall health.
成骨不全症(OI)是一种罕见的遗传性骨骼脆弱性结缔组织疾病,发病率约为 1:15000。大约 85%导致 OI 的致病变异存在于 I 型胶原基因 COL1A1 和 COL1A2 中,其余致病 OI 变异至少跨越 20 个额外的遗传位点,这些变异通常涉及 I 型胶原的翻译后修饰、折叠和细胞内运输以及基质掺入和矿化。I 型胶原不仅是体内最丰富的胶原,也是多个器官系统和组织中重要的结构和细胞外基质信号分子。因此,OI 致病变异不仅导致骨骼脆弱、骨密度降低、脊柱后凸和身材矮小,还可能导致听力损失、牙本质发育不全、蓝灰色巩膜、心肺异常和肌肉无力。OI 广泛的遗传和临床异质性使得需要生成多种小鼠模型,越来越意识到非骨骼器官和组织的参与,以及 OI 更广泛地被认为是一种 I 型胶原病。这推动了对突变特异性骨骼和骨骼外表现的研究,并拓宽了潜在机制治疗策略的探索。本文的目的是概述最近通过使用具有遗传和表型异质性的成骨不全症小鼠模型所描述的几种骨骼外表现,展示 OI 致病变异作为胶原病(影响多个器官系统和组织)的显著潜在影响及其对整体健康的意义。